Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

References

• Greco F. Metastatic renal cell carcinoma: an invincible enemy? Eur Urol 2013;63:653-4
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-4
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2013. Atlanta, GA: American Cancer Society, 2013
   Google Scholar
• Shih YC, Chien CR, Xu Y, et al. Economic burden of renal cell carcinoma. Pharmacoeconomics 2011;29:315-29
   PubMed Web of Science ®Google Scholar
• Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with renal cell carcinoma in the United States. Urol Oncol 2007;25:368-75
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66
   PubMed Web of Science ®Google Scholar
• U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. 2013. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2013
   Google Scholar
• National Cancer Institute (US). Drug approved for kidney (renal cell) cancer [Internet]. Bethesda, MD: National Cancer Institute at the National Institutes of Health, 2013. http://www.cancer.gov/cancertopics/druginfo/kidneycancer. Accessed December 17, 2013
   Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology: kidney cancer. Fort Washington, PA: National Comprehensive Cancer Network, 2014
   Google Scholar
• Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer 2013;11:161-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Everolimus [Internet]. Silver Spring, MD: U.S. Department of Health and Human Services, 2010. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm127799.htm. Accessed December 16, 2013
   Google Scholar
• Motzer RJ, Escudier B, Oudard SP, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2009;372:449-56
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010;116:4256-65
   PubMed Web of Science ®Google Scholar
• Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (Oxf) 1990;48:333-9
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Axitinib [Internet]. Silver Spring, MD: U.S. Department of Health & Human Services, 2012. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm. Accessed December 16, 2013
   Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Schmitz S, Broom R. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol 2013;139:1917-26
   PubMed Web of Science ®Google Scholar
• Sherman SA, Wang X, Amzal B, et al. A Weighted-adjusted indirect comparison of Everolimus (EVE) versus Axitinib (AXI) in Second-line Metastatic Renal Cell Carcinoma (mRCC) patients who previously failed sunitinib therapy. Poster presented at the 2014 Genitourinary Cancers Symposium in San Francisco, CA from January 30, 2014 to February 1, 2014
   Google Scholar
• RECORD-1 Trial [Data on file]. Novartis Pharmaceuticals Corporation, 2013. https://clinicaltrials.gov/ct2/show/NCT00410124?term=record-1&rank=1
   Google Scholar
• Delea TE, Khuu A, Heng DY, et al. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer 2012;107:1059-68
   PubMed Web of Science ®Google Scholar
• Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Statist Med 1990;9:1259-76
   PubMed Web of Science ®Google Scholar
• Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Statist Med 1998;17:1215-29
   PubMed Web of Science ®Google Scholar
• Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Contr Clin Trials 2003;24:682-701
   PubMedGoogle Scholar
• Afinitor(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012
   Google Scholar
• Inlyta(R) [FDA Briefing Document]. Oncologic Drugs Advisory Committee Meeting. Silver Spring, MD: FDA, 2011
   Google Scholar
• Pal S, Perrin A, Chua A, et al. The lifetime cost of Everolimus vs. Axitinib in metastatic renal cell carcinoma patients who have failed prior sunitinib therapy in the US. Poster presented at the 12th International Kidney Cancer Symposium in Chicago, IL from October 25, 2013 to October 26, 2013
   Google Scholar
• Ismail N, Zamani H. Estimation of claim count data using negative binomial, generalized poisson, zero-inflated negative binomial and zero-inflated generalized poisson regression models. Casaulty Actuarial Society E-Forum, Spring 2013
   Google Scholar
• Coxe S, West SG, Aiken LS. The analysis of count data: a gentle introduction to poisson regression and its alternatives. J Pers Asses 2009;91:121-36
   PubMed Web of Science ®Google Scholar
• Ozer-Stillman I, Keyser R, Ambavane A, et al. Sorafenib versus axitinib for second-line treatment of patients with advanced renal cell carcinoma (RCC) in the United States (US): an economic evaluation. Poster presented at the 37th ESMO Congress in Vienna, Austria from September 28, 2012 to October 2, 2012
   Google Scholar
• Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. RED BOOK Drug References, c2014. Thomson Reuters; c2014. http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red. Accessed July 17, 2014
   Google Scholar
• Find A Code, LLC [internet]. Find-A-Code. Spanish Fork, UT: 2000-2014. http://www.findacode.com/. Accessed June 23, 2013
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). 2013. Rockville, MD: Agency for Healthcare Research and Quality, 2012
   Google Scholar
• Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-[alpha]2a compared with sunitinib. Br J Cancer 2009;102:80-6
   PubMed Web of Science ®Google Scholar
• Dial E, Fournier A, Moyneur E, et al. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. J Clin Oncol 2008;26:15 suppl 14609
   Web of Science ®Google Scholar
• Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. RED BOOK Drug References; c2013. Thomson Reuters, c2013. http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micromedex_clinical_evidence_sols/med_safety_solutions/red. Accessed June 26, 2013
   Google Scholar
• Zhang B, Wright AA, Huskamp HA. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med 2009;169:480-8
   PubMed Web of Science ®Google Scholar
• Matias M, Albiges L, Ablard C, et al. Real world experience with axitinib in renal cell carcinoma at Institut Gustave Roussy (IGR). Poster presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam, Netherlands from September 27, 2013 to October 1, 2013
   Google Scholar
• Crystal S, Akincigil A, Bilder S, et al. Studying prescription drug use and outcomes with Medicaid claims data strengths, limitations, and strategies. Med Care 2007;45(10 Suppl):S58-S65
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
   Google Scholar